[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:thyroid-gland-anaplastic-carcinoma":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":48,"states":49},"Thyroid Gland Anaplastic Carcinoma",6,5,[8,16,22,29,35,41],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT03975231","Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer",[12],"Phase 1","RECRUITING","2026-08-26T02:19:19.975067Z","2026-05-05T02:43:28.643652Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT06902376","XL092 and Cemiplimab in BRAF WT Thyroid Cancer",[12],"2026-08-26T02:17:38.215063Z","2026-05-05T02:43:27.657984Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":27,"content_modified":28},"NCT06007924","A Study of Avutometinib and Defactinib in People With Thyroid Cancer",[26],"Phase 2","2026-08-26T02:19:19.162260Z","2026-05-05T02:43:27.103317Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT05503797","A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations",[26],"2026-08-26T02:19:21.761002Z","2026-07-30T01:46:14.464355Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":39,"content_modified":40},"NCT06507878","Global Real World Data in Patients With Advanced Thyroid Cancer on Standard of Care and Specialized Interventions- Registry of Oncologic Outcomes With Testing and Treatment.",[],"2026-08-26T02:18:56.409949Z","2026-05-13T02:55:06.496306Z",{"nct_id":42,"title":43,"phases":44,"status":45,"updated_at":46,"content_modified":47},"NCT07470489","Zanzalintinib Plus Cemiplimab for the Treatment of BRAF Wild-Type Anaplastic Thyroid Cancer",[26],"NOT_YET_RECRUITING","2026-08-26T02:18:21.216897Z","2026-05-05T02:43:29.368979Z",[],[50],{"state":51,"count":52,"slug":53},"Texas",4,"texas"]